Eupraxia Pharmaceuticals, Inc. (EPRX) - Market Value to Book Value Ratio
Eupraxia Pharmaceuticals (EPRX) automates the production of extended-release agents by combining robotic lines with expert clinical process management. The startup is currently preparing its depot drug platform for market entry, finalizing tests and selecting distributors. The indicator stands at 4.70. Historical price action demonstrates the potential of prolongation technologies, which transform proven molecules into stable cash cows.
Eupraxia Pharmaceuticals (EPRX) - metric breakdowns and financial figures
- share price and consensus valuation forecast:
- market capitalization indicators:
- book capitalization data:
- debt obligations and liquidity statistics:
Debt to Equity Eupraxia Pharmaceuticals|EPRX - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity eupraxiapharma.com|EPRX - Company Total Debt|Debts to Book Capitalization Eupraxia Pharma|EPRX - Company Long-Term Debts|Company Current Liabilities Eupraxia Pharmaceuticals|Quick Liquidity eupraxiapharma.com
- earnings and valuation multiples indicators:
Basic company analysis:Eupraxia Pharmaceuticals, Inc. - EPRX
Eupraxia Pharmaceuticals is transforming rehabilitation through its DiffuCORE technology, providing a prolonged analgesic effect for Librexia. The price-to-book ratio determines the size of the investment premium over assets, reflecting market confidence in the company's intellectual property, which allows for an assessment of correction risk through the historical price-to-book trend.
Competitor analysis
HLN (Haleon plc) - Market Cap to Net Assets Ratio|Capitalization to Book Value Ratio KVUE|Market Value to Book Value Ratio Verona Pharma|Jyong Biotech Limited - Market Capitalization to Net Assets|Market Capitalization to Book Value Ratio LGND|AMRX (Amneal Corp) - Market Value to Book Value|Market Capitalization to Book Value Ratio PRGO (Perrigo Company plc)|Market Capitalization to Book Value Ratio alvotech.com ALVO|LQDA - Market Value to Book Value Ratio|Market Value to Book Value GLPG (Galapagos N.V.)|ANI Pharma (ANIP) - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio Afrezza|AMPH (Amphastar Pharmaceuticals) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio pacira.com|Market Cap to Net Assets Ratio SPRY (ARS Pharmaceuticals, Inc.)|TBPH (Theravance Biopharma Inc) - Market Value to Book Value|Market Value to Book Value Ratio Aquestive Pharma AQST|scPharmaceuticals, Inc. (SCPH) - Market-to-Book Ratio|TECX: Market Cap to Net Assets Ratio|tonixpharma.com - Market Cap to Book Value Multiple|SXTC: Market Capitalization to Book Value Ratio|BioHarvest Sciences, Inc. - Market Value to Book Value|EXOZ (Invizyne Technologies, Inc.) - Market Capitalization to Book Value Ratio|Market-to-Book Ratio Oramed Pharma ORMP|Market Value to Book Value Ratio Entera Bio Ltd. (ENTX)|HYFT (ipatherapeutics.com) - Market Value to Book Value|Market Capitalization to Book Value Ratio ABVC (ABVC BioPharma, Inc.)|Cumberland Pharmaceuticals Inc (CPIX) - Market-to-Book Ratio|QNTM: Market Cap to Net Assets Ratio|FGEN - Market Capitalization to Book Value Ratio|Telomir Pharmaceuticals (TELO) - Market Value to Book Value Ratio|Market Capitalization to Net Assets RANI (Rani Therapeutics Holdings, Inc.)|Market Value to Book Value Ratio Synergy CHC Corp.|RLYB: Market Value to Book Value|Market Capitalization to Book Value Ratio LEXX|Market Capitalization to Book Value Ratio Pulmatrix Corporation (PULM)|Pheton Holdings - Market Cap to Net Assets Ratio|APM: Capitalization to Book Value Ratio|Lyra Therapeutics - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value impactbiomedinc.com IBO|TNFA: Market Capitalization to Book Value Ratio|cbdMD (YCBD) - Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio PRFX|CYTO: Market Value to Book Value|Market Value to Book Value Ratio Lipella Pharmaceuticals, Inc. (LIPO)|OPTN: Market Capitalization to Net Assets|Market Capitalization to Book Value Ratio PIRS (Pieris)|Market Value to Book Value PROC|Petros Pharmaceuticals - Market Capitalization to Book Value Ratio|QLI - Market Capitalization to Book Value Ratio|ACELYRIN (SLRN) - Market Value to Book Value Ratio|TFF Pharmaceuticals Inc. - Market Value to Book Value